PMID- 35868498
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20220823
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 177
DP  - 2022 Sep
TI  - Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? 
      A systematic review and meta-analysis.
PG  - 103758
LID - S1040-8428(22)00182-2 [pii]
LID - 10.1016/j.critrevonc.2022.103758 [doi]
AB  - Antibody-drug conjugates (ADCs) show significant advantages in cancer treatment 
      due to their high selectivity and anti-tumor activity, but the efficacy and 
      safety of the treatment of solid tumors are unknown. We searched research 
      databases, major conference proceedings and trial registries for randomized 
      controlled trials (RCTs). Then, we selected qualified studies and extracted 
      dates. Studies were assessed for quality, and a meta-analysis was conducted to 
      quantify effects of ADCs on overall survival (OS), progression-free survival 
      (PFS), overall response rate (ORR) and adverse events (AEs). The within-study 
      heterogeneity was evaluated by subgroup and sensitivity analysis. Eleven RCTs 
      with 4353 participants were included. ADCs had better PFS (HR: 0.69, 95 % CI: 
      0.56-0.82) and OS (HR: 0.76, 95 % CI: 0.61-0.92). ADCs resulted in lower risk of 
      febrile neutropenia in blood system. Conversely, ADC therapy had not a prepotent 
      on ORR (RR: 1.36, 95 % CI: 0.71-2.60).
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Zhang, Leyin
AU  - Zhang L
AD  - Department of Medical Oncology, Hangzhou TCM Hospital of Zhejiang Chinese Medical 
      University, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou 310005, 
      China.
FAU - Shen, Deyi
AU  - Shen D
AD  - The First School of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou 310053, China.
FAU - Yu, Lulin
AU  - Yu L
AD  - The First School of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou 310053, China.
FAU - Yan, Yici
AU  - Yan Y
AD  - The First School of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou 310053, China.
FAU - Wasan, Harpreet S
AU  - Wasan HS
AD  - Department of Cancer Medicine, Hammersmith Hospital, Imperial College Healthcare 
      NHS Trust, London W2 1NY, UK.
FAU - Yu, Jieru
AU  - Yu J
AD  - School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 
      310053, China. Electronic address: jieruyu@zcmu.edu.cn.
FAU - Zhang, Shuo
AU  - Zhang S
AD  - The Second Affiliated Hospital of Zhejiang Chinese Medical University, Xinhua 
      Hospital of Zhejiang Province, Hangzhou 310005, China. Electronic address: 
      zhangshuotcm@163.com.
FAU - Sun, Leitao
AU  - Sun L
AD  - Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese 
      Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, 
      Hangzhou 310000, China. Electronic address: sunnylt@zcmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220720
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunoconjugates)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects
MH  - Humans
MH  - *Immunoconjugates/adverse effects
MH  - *Neoplasms/chemically induced/drug therapy
OTO - NOTNLM
OT  - Antibody-Drug Conjugate
OT  - Efficacy
OT  - Meta-Analysis
OT  - Safety
OT  - Solid Tumor
EDAT- 2022/07/23 06:00
MHDA- 2022/08/24 06:00
CRDT- 2022/07/22 19:25
PHST- 2022/05/14 00:00 [received]
PHST- 2022/07/07 00:00 [revised]
PHST- 2022/07/14 00:00 [accepted]
PHST- 2022/07/23 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
PHST- 2022/07/22 19:25 [entrez]
AID - S1040-8428(22)00182-2 [pii]
AID - 10.1016/j.critrevonc.2022.103758 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2022 Sep;177:103758. doi: 
      10.1016/j.critrevonc.2022.103758. Epub 2022 Jul 20.